OmniAb, Inc.
David Mowrey has extensive work experience in the field of scientific research and development. David currently holds the position of Principal Scientist at OmniAb, Inc. since November 2022.
Prior to this, they worked at Icagen, where they held the roles of Principal Scientist from February 2021 to November 2022 and Senior Research Scientist from April 2017 to February 2021.
David also served as a Postdoctoral Researcher at both the University of North Carolina at Chapel Hill from November 2014 to March 2017 and the University of Pittsburgh School of Medicine from May 2014 to October 2014.
David Mowrey's research expertise includes performing molecular dynamics simulations, analyzing NMR data, and conducting functional validation experiments.
David began their scientific career as a Graduate Student at the University of Pittsburgh from August 2008 to May 2014, where they focused on the examination of anesthetic effects on nicotinic acetylcholine receptors using computational and experimental approaches.
David Mowrey gained early research experience as an Intern at Leadscope, Inc. in May 2007 and as a Summer Replacement Student at Eli Lilly and Company in May 2005.
David Mowrey has a strong educational background in the field of biology and computational biology. David earned their Bachelor of Science (BS) degree in Biochemistry Molecular Biology from Wittenberg University from 2004 to 2008. Following that, they pursued their Doctor of Philosophy (Ph.D.) degree in Computational Biology at the University of Pittsburgh from 2008 to 2014.
In addition to their formal education, David Mowrey has also obtained several certifications in the field of machine learning. In November 2017, they completed the courses "Improving Deep Neural Networks: Hyperparameter Tuning, Regularization, and Optimization" and "Structuring Machine Learning Projects" offered by Coursera. In October 2017, they completed the course "Neural Networks and Deep Learning" from the same institution.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.